A Predictive Tool for Antibody Drug Conjugates

The right treatments. The right patients.

Antibody drug conjugates (ADCs) are targeted chemotherapy designed to bring the chemotherapeutic drug to the cancer cells while sparing normal tissue.

ADCs are at the forefront of new anticancer treatment with more than 170 different ADCs evaluated in clinical trials and 12 clinically approved. Despite their success, ADCs have complex toxicity profiles and there is a variability of response among patients. Thus, many patients experience suboptimal treatment with severe side effects and a reduced chance of response. There is a critical need to improve ADC patient stratification and select the right treatment to each patient.

The Problem

Infographic showing ADC treated population outcomes without Rab Diagnostics technology, showing a group of people split into responders and non-responders.

Current practise in ADC patient selection includes identification of the cancer cell surface marker to which the ADC bind. This practise does not take into account that ADCs needs to be taken up into the cell in order to exert their effect. Our work has focused on identifying intracellular proteins that determine ADC response. We have shown that these proteins can be used as predictive biomarkers for ADCs and thereby  refine patient selection and overall response.

Vertical text reading "Science" in blue font with a period at the end.

The Solution

Infographic illustrating ADC treated population using Rab Diagnostics technology to select patients that will respond to treatment.

The word 'Impact' written vertically in blue text.

ADC patient stratification holds profound implications for both cancer treatment and drug development.

Patients

Hospital bed icon with red cross symbol

Improved patient selection for ADC treatments will increase the response rate and spare patients that are unlikely to respond from treatment that is not working.

Pharma Companies

Icon of a medicine bottle with a cross and two capsules.

Enabling the selection of the right patients for clinical ADC trials, with the potential to increase the response rate and reduce costs and risk in ADC development.

Health Care Providers / Payers

Red cross inside a navy blue circle logo

Selecting the right patients has the potential to save significant costs and provide rational use of limited resources.

Finding the right patients

ADCs represent a new era in cancer treatment. However, there is still a pressing need for advanced biomarker insight to optimize patient selection.

Our data show that Rab-GTPases, a protein crucial in endocytosis, impact ADC efficacy in patients. Furthermore, we have demonstrated that quantification of specific Rab-GTPases expression can be used as a predictive biomarker for ADC response. We have developed proprietary tools, models and assays that predict the response of ADCs to support precision medicine in oncology.

Vertical text of the word 'Potential' in white on a black background
An illustration of how a RAB Diagnostics test kit could look like.
RAB Diagnostics kit illustration on wooden surface.
The word "Services" written vertically in blue text on a white background.

Discovery/Preclinical

• In vitro cell based models

• Histology studies

• Gene (RNA) /Protein (IHC/IF) expression

• Rab-GTPase RUO kit development

Flowchart depicting stages of drug development: Discovery, Preclinical, Clinical Trials, Commercial.

Benefits

• Understand response rate

• Disease/Market strategy

• Decreased risk and costs

• Improved probability of success

Clinical trials

• Rab-GTPases biomarker prevalence

• Translational studies

• Clinical trial patient selection and stratification

• Diagnostic kit development

Benefits

• Understand ADC MoA

• Biomarker identification

• Lead candidate selection

• Informed decisions

Commercial

• Dx/Rx co-launch

• Complementary diagnostics

• Companion diagnostics

Benefits

• Faster market access

• Improved clinical acceptance and adoption

• Differentiation in the market

Text listing benefits of RabGTPase research and ADCs, including expert guidance, leading research, translatable models, clinical collaborations, AI scoring, and custom study design.
Vertical text "Capabilities" in blue font.
Vertical text spelling "Team" in blue font on a white background.

Management Team

Founder and CEO Anette Weyergang

  • Researcher and entrepreneur within targeted cancer therapeutics. Strong scientific track record within experimental therapeutics and drug delivery. She is a project group leader at Oslo University Hospial and has a solid network of researchers, clinicians and health science innovators. Anette is PhD and Master of Pharmacy from Oslo University Norway.

COO Audun Thornes

  • With over 25 years of experience in the pharmaceutical and biotech industries, Audun brings deep expertise to diagnostic and therapeutic development, spanning from early research through clinical trials. His background includes international line and project management roles within large pharmaceutical companies, as well as CEO/COO positions in biotech startups.

    Audun possesses a strong track record in product development and technology commercialization. He is inventor of 10 patents in diagnostics and cancer therapy and offers extensive experience in intellectual property strategy and management. Audun holds an MSc in Applied Physics from Linköping Institute of Technology.

CTO and Head of Business Development Hans Christian pedersen

  • With more than 20 years of experience, Hans Christian is a seasoned leader with competencies both in cancer diagnostic development combined with a decade of commercial leadership. He has a strong track record of advancing innovative diagnostic solutions , including FDA-approved companion diagnostics and high-impact clinical services across molecular diagnostics, pathology, and early cancer detection.

    His experience spans both entrepreneurial and corporate environments, with deep expertise in development, regulatory, product management, marketing and sales of diagnostics. Hans Christian holds a MSc in Molecular Biology from University of Copenhagen.

Board of Directors

man wearing glasses and a gray blazer smiling at the camera against a white background.

  • Medical doctor with extensive experience from the Pharmaceutical Industry. He is chairman of the board for Oslo Cancer Cluster and has solid experience with start- up companies within health science.

    Øyvind is dr. med from Oslo University, Norway

Person with shoulder-length blonde hair, wearing a black sweater and necklace, smiling against a plain white background.

  • Anne Mathilde Kvamme has a strong track record in clinical drug development and has previously been appointed as Head Clinical Operations at Boehringer Ingelheim Norway. She is team leader for research support at Haukeland University Hospital and NorCRIN Board Member.

    Anne Mathilde is Master of Pharmacy from Oslo University, Norway

Smiling older man with glasses, white hair and beard wearing a collared shirt and sweater.

  • Professor, Researcher and innovator within experimental cancer therapy. He has a strong track record on clinical implementation of translational science, and has been fundamental for protected technology behind both Photocure and PCI Biotech.

    Professor Berg is Cand real from Oslo University, Norway

Smiling man with gray hair and beard, wearing a blue suit and tie on a white background.

  • Ole Dahlberg MSc in Genetics with 25+ years’ experience from life science industry including executive leadership roles in international life science companies like Qiagen and Thermo Fisher Scientific, where until 2021 he was the vice-President and general manager with responsibility for the Cell Biology Division. He has co-founded three start-up companies where he has worked on both the commercial and R&D side.

Portrait of a mature man in a white coat smiling at the camera; medical professional

Scientific Advisory Board

  • Attending oncologist & senior scientist at Oslo University Hospital and associated professor at University of Oslo. He has more than 20+ years in clinical research and has participated in several clinical committees, working groups & boards. Since 2003 he has been involved, both as principal & co-investigator, in setting up & implementing clinical trials incl. multicentre, randomized phase II studies, and as a national coordinating PI in phase III studies. Olav is dr.med. from University of Bergen, Norway

Portrait of a woman with short hair smiling in a dark jacket.

  • Award-winning Chief Scientific Officer, Committee Member and Senior Leader. She has expertise in the fields of Personalized Medicine and Cancer Diagnostics where she driven innovations and product commercialization for leading biotechnology companies, including multiple Companion Diagnostics products, in partnership with pharma

Logos of Oslo University Hospital, Oslo Cancer Cluster, RADFORSK, and Oslo Cancer Cluster Incubator on a teal background.
Vertical text displaying the word "Collaboration" in blue.

Logos for Oslo University Hospital, Oslo Cancer Cluster, Oslo Cancer Cluster Incubator, and RADFORSK on a teal background.
Logos of Oslo University Hospital, Oslo Cancer Cluster, Oslo Cancer Cluster Incubator, RADFORSK on turquoise background.

We deeply value collaboration.
Reach out and let’s make an impact.

The word "contact" written vertically in blue letters on a white background.